Tarsus Pharmaceuticals, a Phase 3 biotech developing therapies for ophthalmic conditions, raised $88 million by offering 5.5 million shares at $16, within the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company raised 10% more in proceeds than expected.
Tarsus Pharmaceuticals plans to list on the Nasdaq under the symbol TARS. BofA Securities, Jefferies, Raymond James, LifeSci Capital and Ladenburg Thalmann acted as joint bookrunners on the deal.
